Study Type
Interventional - Drug
completed
The purpose of the GENETIC-AF study was to determine if pharmacogenetically targeted bucindolol is superior to Toprol-XL for reducing the recurrence of symptomatic atrial fibrillation/atrial flutter (AF/AFL) in a genotype-defined population with heart failure and/or reduced left ventricular ejection fraction (LVEF) and persistent symptomatic AF requiring electrical cardioversion to sinus rhythm.
Primary endpoint:
Time to first event of symptomatic atrial fibrillation/atrial flutter (AF/AFL) or all-cause mortality (ACM) during the 24-week follow-up period after conversion to stable sinus rhythm.
Study Design
Double blind 2 arm active controlled adaptive design superiority
NO. of Countries
6
NO. of Sites
113
NO. of Participants
267
Study Period
2014 - 2017
Sponsor
ARCA Biopharma
Jeff Healey
Senior Scientist
Jeff Healey
Senior Scientist
Jeff Healey is a Cardiologist/Electrophysiologist and Professor of Medicine at McMaster University. He is Yusuf Chair and Director of Cardiology at McMaster University. He is the chair of the Canadian Stroke Prevention and Intervention Network (CSPIN) and past chair of the Canadian Atrial Fibrillation guidelines committee. He is also on the steering committee of the international AF Screen organization.
Healey was the lead author of the ASSERT trial that demonstrated the increased stroke risk associated with sub-clinical atrial fibrillation (New England Journal of Medicine 2012), and the principal investigator of the ARTESIA trial, which demonstrated that anticoagulation with apixaban reduced the risk of stroke in patients with sub-clinical atrial fibrillation New England Journal of Medicine 2023). He is also the principal investigator of the LAAOS-4 trial, evaluating the role of left atrial appendage occlusion on top of NOAC therapy for prevention of stroke in high-risk individuals with atrial fibrillation.
